Florham Park-based Shionogi & Co., Ltd. announced FETROJA® (cefiderocol) is now available in the U.S. for patients 18 years of age or older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, caused by the following susceptible Gram-negative microorganisms: Escherichia coli (E. coli), Klebsiella pneumoniae (K. pneumoniae), Proteus mirabilis (P. mirabilis), Pseudomonas aeruginosa (P. aeruginosa), and Enterobacter cloacae (E. cloacae) complex

Bridgewater-based  Menlo Therapeutics Inc. announced the completion of its merger with  Foamix Pharmaceuticals Ltd. following the satisfaction of all closing conditions required by the merger agreement.  Upon completion of the merger, Foamix became a wholly-owned subsidiary of Menlo. "This is an exciting day as we take a significant step toward becoming a broad dermatology franchise. The combined company already has an approved, commercial-stage product, AMZEEQ, and several late-stage product candidates with several meaningful near-term catalysts," said David Domzalski, who became the Chief Executive Officer of Menlo upon the closing of the merger.

Hackensack-based  BrainStorm Cell Therapeutics Inc.  announced that it has entered into a definitive agreement with  Abbhi Investments, LLC  in connection with a privately negotiated sale of common stock and a warrant to purchase common stock (collectively, the "securities"). BrainStorm intends to use the proceeds from this transaction to fund its operations, which includes, but is not limited to advancing the company's clinical programs, commercial production of the investigational therapeutic NurOwn® (whether for ALS or other indications), regulatory, pre-marketing and commercialization preparation activities of NurOwn® for ALS, working capital and general corporate purposes.

Eatontown-based Hikma Pharmaceuticals PLC and Glenmark Specialty S.A., a Swiss subsidiary of Glenmark Pharmaceuticals announced the signing of an exclusive U.S. license agreement to commercialise Ryaltris™ (olopatadine hydrochloride and mometasone furoate nasal spray), an investigational fixed-dose combination nasal spray for the treatment of seasonal allergic rhinitis (SAR). Under the terms of the agreement, Glenmark will be responsible for the continued development and regulatory approval of Ryaltris™ by the US Food and Drug Administration (FDA). Hikma will be responsible for the commercialisation of Ryaltris™ in the U.S. following approval.

DBV Technologies, with offices in  Summit, announced that the underwriters for its previously announced global offering have partially exercised their option to purchase 338,687 additional ordinary shares in the form of 677,374 American Depositary Shares ("ADSs"), at an offering price of $10.25 per ADS, before deducting commissions and estimated offering expenses (the "Option"). The company plans to use the net proceeds from the global offering, together with its existing cash and cash equivalents, primarily to prepare for the commercialization of Viaskin Peanut, including marketing efforts related to launch in the second half of 2020, if approved.

Cranbury-based BioNJ Member Rafael Pharmaceuticals, Inc.  announced the appointment of Sanjay Sehgal, Ph.D., to Chief Regulatory Affairs and Quality Assurance Officer. The newly created position is indicative of the company's continued commitment and dedication to adhere to global governmental regulations and standards, surrounding its lead compound CPI-613® (devimistat). Dr. Sehgal has more than 25 years of experience working with both multinational and small biotechnology companies. Most recently, he served as the Senior Vice President of Regulatory Affairs and Conformance at Celularity,

Morris Plains-based BioNJ Member  Immunomedics, Inc.  announced the appointment of Robert W. Azelby to the Company's board of directors. Mr. Azelby is a biotech industry veteran with 28 years of biopharmaceutical experience with a large emphasis on commercialization. Mr. Azelby was recently the president and chief executive officer, and a member of the board of directors, of Alder BioPharmaceuticals, Inc. Previously, Mr. Azelby served as Executive Vice President, Chief Commercial Officer of Juno Therapeutics, Inc. where he was responsible for the development and implementation of Juno's CAR-T commercial strategy and helped guide the organization through rapid growth and ultimately to a $9 billion acquisition by Celgene Corporation.

Bridgewater-based  Amneal Pharmaceuticals Inc.  announced Tasos Konidaris was appointed as Senior Vice President, Chief Financial Officer. Mr. Konidaris brings more than 30 years of corporate finance and leadership experience, including in the pharmaceutical and business analytics and data industries. Mr. Konidaris most recently served as Chief Financial Officer and as a board member of Alcresta Therapeutics Inc. Prior to that, he served as Executive Vice President, Chief Financial Officer and Head of Corporate Development of Ikaria Inc.

It is evident that t he cell and gene therapy sectors are growing faster than the field of available talent, pressuring start-ups and established players alike.  That was the key driver for the Talent Development Ideation Meeting, held on NJIT's campus . NJII's Biotechnology & Pharmaceutical Innovation iLab hosted more than a dozen leading biopharma executives from business, government and academia in a roundtable discussion to strategize ways of attracting, training and retaining talent to the industry. Dr. Peter Marks, the director of the Center for Biologics Evaluation and Research at the Food and Drug Administration (FDA), served as the event's keynote speaker.

Pursuant to Executive Order 103 (Murphy 2020) ("EO 103") in response to increasing numbers of employers encouraging employees to work from home in response to the COVID-19 pandemic, the New Jersey Economic Development Authority (NJEDA) is waiving certain specific requirements related to employee presence in the office for the recipients of awards under employment-based incentive programs. 

The  New Jersey Economic Development Authority (NJEDA)  announced that it will host a series of  NJEDA Roadshow  events, designed to raise awareness of the Authority's resources for municipalities, communities and businesses of all sizes across all sectors. The events, which will be held in all 21 counties, are being created in coordination with economic development partners at the county and municipal levels. The NJEDA is committed to making New Jersey a national model for inclusive and sustainable economic development by focusing on key strategies to help build strong and dynamic communities, create good jobs for New Jersey residents, and provide pathways to a stronger and fairer economy.